octreotide.txt

CLINICAL USE

Relief of symptoms of gastroenteropancreatic endocrine tumours and acromegaly

DOSE IN NORMAL RENAL FUNCTION

50 micrograms – 1.2 mg daily

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :1019.2 (as acetate)

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :65

%Excreted unchanged in urine &nbsp &nbsp : 32

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :0.27

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :1.5/Increased

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : Dose as in normal renal function

10 to 20 &nbsp &nbsp : Dose as in normal renal function

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. Dose as in normal renal function

HDF/high flux &nbsp :Dialysed. Dose as in normal renal function

CAV/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Ciclosporin: ciclosporin concentration reduced

ADMINISTRATION

Reconstition

Route

SC, IV

Rate of Administration

IV bolus with ECG monitoring

Comments

IV: sodium chloride 0.9% to a ratio of not less than 1:1 and not more than 1:9

OTHER INFORMATION

SC: to reduce local discomfort, warm to room temperature before injectionFor multiple injections, use different sites Patients with reduced renal function have been shown to have a reduced clearance of the drug (75 mL/minute vs. 175 mL/minute).

Tags: post-by-auto-php